GERN Healthcare

Geron Corporation

$0.93+0.00%

Price as of close on Nov 3, 2026 · Financials updated Nov 4, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 597.5M USD
Enterprise value: 809.2M USD
Full-time employees: 258

Overall health

Strength: growing faster than most peersgrowing faster than peers
Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: more debt relative to equity (0.55× vs a peer median of 0.22×)more debt vs equity (0.55× vs peers 0.22×)

Ranks #646 of 1,157 healthcare companies (bottom 45%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Geron looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Growing fast, still losing money. Revenue grew faster than 95% of peers, at an operating loss.
Revenue grew faster than 95% of peers, but the business runs at an operating loss (margin -28%).

StockQuotient Score

49/ 100

Oct 5 49 → Nov 4 49

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-11.3%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-8.6%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-19.2%

Yahoo Finance fallback · SEC cash flow or share count unavailable · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield36.6%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

96/100

Strong

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth575.7%

Yahoo Finance fallback · SEC figure unavailable or out of date · 3 fiscal years to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score 8.59Sector median: 0.0584 · MAD: 0.0840

Revenue growth138.8%

Yahoo Finance fallback · SEC figure unavailable or out of date · fiscal year to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score 10.15Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

24/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-28.0%

Yahoo Finance fallback · SEC operating income not reported in standard form · fiscal year to Dec 2025Reported value33% base weight · Z-score -2.88Sector median: 0.0706 · MAD: 0.1217

Return on assets-13.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -2.74Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-14.8%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.94Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin58.5%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-30.9%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.61

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 0.04Sector median: 0.6250 · MAD: 0.3380

Current ratio6.92×

SEC filings · latest balance sheetReported value33% base weight · Z-score 3.13Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.55×

SEC filings · latest balance sheetReported value33% base weight · Z-score -1.61Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Geron

Is Geron getting weaker?: Its latest SEC filing (Aug 5, 2026) showed no major changes. Its overall score is unchanged at 49/100 since Oct 28, 2026.
How is Geron valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -11.3% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -11.3% vs peers 1.5% (weaker than 100% of peers).
Is Geron growing?: Yes, faster than most of its peers. Growth scores 96/100 against 1,393 healthcare peers. 3-year revenue growth 575.7% vs a peer median of 5.8% (stronger than 95% of peers).3-year revenue growth 575.7% vs peers 5.8% (stronger than 95% of peers).
How profitable is Geron?: Less profitable than most of its peers. Profitability scores 24/100 against 1,393 healthcare peers. Operating margin -28.0% vs a peer median of 7.1% (weaker than 80% of peers).Operating margin -28.0% vs peers 7.1% (weaker than 80% of peers).
How risky is Geron?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 6.92× vs a peer median of 2.59× (stronger than 81% of peers).Current ratio 6.92× vs peers 2.59× (stronger than 81% of peers). Debt / equity 0.55× vs a peer median of 0.22× (weaker than 68% of peers).Debt / equity 0.55× vs peers 0.22× (weaker than 68% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 5, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

	Previous quarter	Latest quarter	Change
Net income (12 months)	−67.3M USD	−67.6M USD	+0.5%
Debt	119.8M USD	120.1M USD	+0.2%
Cash	68.9M USD	62.6M USD	−9.1%
Shares outstanding	641.5M	642.5M	+0.1%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Operating margin	-8183.7%	-23246.6%	-81832.9%	—	—	—
Net margin	-8335.4%	-23808.9%	-77690.7%	—	—	—
Return on assets (ROA)	-51.4%	-74.5%	-46.7%	-29.4%	-14.6%	▲ 15 pts
Return on equity (ROE)	-91.8%	-177.4%	-74.3%	-62.3%	-37.0%	▲ 25 pts
Free cash flow margin	-6874.6%	-21444.6%	-71127.8%	—	—	—
Current ratio	4.11×	2.35×	3.16×	5.56×	4.66×	▼ 16%
Quick ratio	—	—	—	5.12×	3.62×	▼ 29%
Debt to equity	0.39×	0.64×	0.33×	0.42×	0.53×	▲ 25%
Interest coverage	-30.48×	-20.13×	-23.33×	-9.39×	-2.10×	▲ 78%

GERN price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: more debt relative to equity (0.55× vs a peer median of 0.22×)more debt vs equity (0.55× vs peers 0.22×)

Ranks #646 of 1,157 healthcare companies (bottom 45%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Geron looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Growing fast, still losing money. Revenue grew faster than 95% of peers, at an operating loss.

Revenue grew faster than 95% of peers, but the business runs at an operating loss (margin -28%).

Questions investors ask about Geron

Is Geron getting weaker?

Its latest SEC filing (Aug 5, 2026) showed no major changes. Its overall score is unchanged at 49/100 since Oct 28, 2026.

How is Geron valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -11.3% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -11.3% vs peers 1.5% (weaker than 100% of peers).

Is Geron growing?

Yes, faster than most of its peers. Growth scores 96/100 against 1,393 healthcare peers. 3-year revenue growth 575.7% vs a peer median of 5.8% (stronger than 95% of peers).3-year revenue growth 575.7% vs peers 5.8% (stronger than 95% of peers).

How profitable is Geron?

Less profitable than most of its peers. Profitability scores 24/100 against 1,393 healthcare peers. Operating margin -28.0% vs a peer median of 7.1% (weaker than 80% of peers).Operating margin -28.0% vs peers 7.1% (weaker than 80% of peers).

How risky is Geron?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 6.92× vs a peer median of 2.59× (stronger than 81% of peers).Current ratio 6.92× vs peers 2.59× (stronger than 81% of peers). Debt / equity 0.55× vs a peer median of 0.22× (weaker than 68% of peers).Debt / equity 0.55× vs peers 0.22× (weaker than 68% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Net income (12 months)

−67.3M USD

−67.6M USD

+0.5%

Debt

119.8M USD

120.1M USD

+0.2%

Cash

68.9M USD

62.6M USD

−9.1%

Shares outstanding

641.5M

642.5M

+0.1%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Operating margin

-8183.7%

-23246.6%

-81832.9%

—

Net margin

-8335.4%

-23808.9%

-77690.7%

—

Return on assets (ROA)

-51.4%

-74.5%

-46.7%

-29.4%

-14.6%

▲ 15 pts

Return on equity (ROE)

-91.8%

-177.4%

-74.3%

-62.3%

-37.0%

▲ 25 pts

Free cash flow margin

-6874.6%

-21444.6%

-71127.8%

—

Current ratio

4.11×

2.35×

3.16×

5.56×

4.66×

▼ 16%

Quick ratio

—

5.12×

3.62×

▼ 29%

Debt to equity

0.39×

0.64×

0.33×

0.42×

0.53×

▲ 25%

Interest coverage

-30.48×

-20.13×

-23.33×

-9.39×

-2.10×

▲ 78%